On 9 December 2024, GSK announced that the National Medical Products Administration (NMPA) of China has accepted for review a new drug application (NDA) for Blenrep® (belantamab mafodotin) in combination with BorDex (bortezomib plus dexamethasone) as a treatment for relapsed or refractory multiple myeloma (RRMM).
This follows the NMPA granting Breakthrough Therapy Designation for the same application in September 2024. In the same month, GSK also announced that Blenrep® in combination with BorDex or PomDex (pomalidomide plus dexamethasone) for RRMM was accepted in Japan.
Also on 9 December 2024, GSK announced results from a planned interim analysis of the DREAMM-7 trial evaluating Blenrep® in combination with BorDex, versus daratumumab in combination with BorDex, as a second line or later treatment for RRMM. The results showed significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse among patients receiving the Blenrep® combination versus the daratumumab comparator.